CorMedix announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) to Neutrolin Catheter Lock Solution for oncology, hemodialysis, and intensive care unit patients, where catheter-related blood stream infections and clotting can be life threatening.
Neutrolin is a combination preventative solution consisting of taurolidine, citrate, and heparin 1000U/mL. Its mechanism of action includes decreasing the triple threat of infection, minimizing infections and biofilm formation, and keeping catheters operating safely and efficiently by optimizing catheter blood flow.
Neutrolin was recently approved by the FDA to enter a planned Phase 3 program.
For more information visit Cormedix.com.